Drug Therapy of Parkinsonism

FOR more than 150 years, Parkinson's disease has been known as one of the major "crippling" neurologic disorders of middle life. Easily recognizable as a clinical entity, it usually begins insidiously, with minimal signs and symptoms that gradually become more pronounced and are followed by a succession of additional manifestations. Ever increasing motor disability occurs, culminating ultimately in most cases in severe invalidism. Despite impressive recent advances in knowledge resulting in some changes in concepts of Parkinsonism, and the development of new agents for its treatment, the cause of this disorder remains unknown, its pathophysiology a subject of speculation, and . . .